NeoGenomics Inc
$ 8.35
2.33%
17 Apr - close price
- Market Cap 1,086,701,000 USD
- Current Price $ 8.35
- High / Low $ 8.55 / 8.23
- Stock P/E N/A
- Book Value 6.49
- EPS -0.84
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.12 %
- 52 Week High 13.74
- 52 Week Low 4.72
About
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Analyst Target Price
$14.19
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-10-28 | 2025-07-29 | 2025-04-28 | 2025-02-18 | 2024-11-05 | 2024-07-29 | 2024-04-30 | 2024-02-20 | 2023-11-06 | 2023-08-08 | 2023-05-08 |
| Reported EPS | 0.06 | 0.03 | 0.03 | -0.2035 | 0.04 | -0.1394 | 0.03 | -0.02 | 0.03 | -0.1473 | -0.05 | -0.09 |
| Estimated EPS | 0.04 | 0.02 | 0.02 | -0.005 | 0.0286 | 0.01 | -0.0023 | -0.05 | -0.02 | -0.07 | -0.11 | -0.15 |
| Surprise | 0.02 | 0.01 | 0.01 | -0.1985 | 0.0114 | -0.1494 | 0.0323 | 0.03 | 0.05 | -0.0773 | 0.06 | 0.06 |
| Surprise Percentage | 50% | 50% | 50% | -3970% | 39.8601% | -1494% | 1404.3478% | 60% | 250% | -110.4286% | 54.5455% | 40% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NEO
2026-04-19 06:09:00
This article provides details on NeoGenomics' (NEO) Q2 earnings, highlighting that the company met earnings estimates. It presents key financial figures including GAAP EPS, revenue, and year-over-year changes, alongside the company's stock performance relative to the industry and S&P 500.
2026-04-16 18:09:20
NeoGenomics (NASDAQ:NEO) shares fell 5.3% on Thursday, closing at $8.2170 with a trading volume significantly below average. The company reported a Q4 EPS of $0.06 and revenue of $190.17 million, exceeding analyst estimates, but still operates with negative net margins. Analyst ratings are mixed, with a consensus "Hold" and an average target price of $11.86, despite some recent target increases.
2026-04-15 19:39:54
NeoGenomics will present eight scientific posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations will highlight the company's work in integrating laboratory testing with clinical data to support oncology research, drive AI-based analysis, and translate findings into clinically relevant insights. Areas of focus include biomarker identification, immuno-oncology, AI applications, hematologic malignancies, tumor microenvironment research, and sarcoma testing.
2026-04-14 09:09:31
NeoGenomics, Inc. has received an average "Hold" recommendation from brokerages, with analysts setting an average 12-month price target of $11.86. Despite beating Q4 EPS and revenue expectations, the company remains unprofitable, and insiders recently sold shares. Financial institutions and hedge funds hold a significant portion of the stock.
2026-04-13 14:39:06
NeoGenomics, Inc. announced it will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026. The presentations will highlight how combining laboratory testing with clinical data can support oncology research and drive AI-based analysis to translate findings into clinically relevant insights. CEO Tony Zook emphasized that integrating lab and clinical data is becoming fundamental to modern oncology research, enhancing therapy development, and creating options for providers and patients.
2026-04-13 12:39:06
NeoGenomics, Inc. will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026, showcasing new research. The presentations highlight how combining laboratory testing with clinical data can support oncology research and drive AI-based analysis, enabling cutting-edge oncology therapy development and commercialization. The company's CEO, Tony Zook, emphasized the foundational role of integrated lab and clinical data in modern oncology research and therapy development.
